Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Early Pregnancy Factor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    145 result(s) found for: Early Pregnancy Factor. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2022-003879-42 Sponsor Protocol Number: 2021/ABM/03/00006 Start Date*: 2023-04-12
    Sponsor Name:Medical Univeristy of Bialystok
    Full Title: A randomized, controlled, double-blind clinical trial evaluating the effect of METformin treatment on endometrial function in women diagnosed with Idiopathic Infertility
    Medical condition: Potential causes of idiopathic infertility include in particular: abnormal function of the endometrium, including implantation disorders and immunological abnormalities, genetic abnormalities and t...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10016471 Fertility and fertilisation interventions female HLT
    20.0 10038604 - Reproductive system and breast disorders 10021928 Infertility female PT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001101-40 Sponsor Protocol Number: 13/0417 Start Date*: 2015-02-24
    Sponsor Name:University College London (UCL)
    Full Title: Sclero XIII: A phase II ,double-blind, randomized, placebo-controlled study to investigate pharmacokinetics (PK), safety and efficacy of intravenous factor XIII treatment in patients with systemic...
    Medical condition: Systemic Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004859 10010759 Connective tissue disorder NOS LLT
    17.1 100000004859 10018124 Generalized scleroderma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022463-35 Sponsor Protocol Number: 3.1 Start Date*: 2011-07-08
    Sponsor Name:Manchester Mental Health and Social Care Trust
    Full Title: The Benefit of Minocycline on Negative Symptoms in Psychosis: Extent and Mechanisms
    Medical condition: schizophrenia
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001428-38 Sponsor Protocol Number: RRK2939 Start Date*: 2006-09-18
    Sponsor Name:University Hospitals Birmingham NHS Foundation Trust
    Full Title: Remission Induction in Very Early Rheumatoid Arthritis (RIVERA): a comparison of etanercept plus methotrexate plus steroid with standard therapy
    Medical condition: Patients with early inflamatory arthritis (duration of symptoms of < 12 weeks) who are at very high risk of the development of rheumatoid arthritis (seropositivity for Rheumatoid factor and anti-C...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002425-21 Sponsor Protocol Number: 11054 Start Date*: 2012-02-10
    Sponsor Name:University of Nottingham
    Full Title: Efficacy of Dehydroepiandrosterone to overcome the effect of ovarian aging
    Medical condition: Women having low ovarian reserve undergoing IVF/ICSI treatment
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000284-21 Sponsor Protocol Number: 524E-CVD-9101-004 Start Date*: 2007-11-08
    Sponsor Name:York Hospitals NHS Foundation Trust [...]
    1. York Hospitals NHS Foundation Trust
    2. University of York
    Full Title: A multicentre, multinational randomised control trial of prophylactic low molecular weight heparin(LMWH) in high risk pregnant thrombophilic women
    Medical condition: Thrombophilia in pregnancy. This is a multi-centre, multi-national randomised controlled trial of Low Molecular Weight Heparin to prevent pregnancy complications in high-risk pregnant thrombophi...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10057396 Thrombophilia LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016731-34 Sponsor Protocol Number: CRO1413 Start Date*: 2010-01-08
    Sponsor Name:Imperial College
    Full Title: Amino acid regimen and intravenous lipid composition in preterm parenteral nutrition: a randomised double blind controlled trial of Nutritional Evaluation and Optimisation in Neonates.
    Medical condition: Preterm birth
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036594 Premature birth LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005407-24 Sponsor Protocol Number: KKIKEM Start Date*: 2015-02-27
    Sponsor Name:IKEM
    Full Title: Effect of early administration of eplerenone in patients after acute myocardial infarction
    Medical condition: Verify the efficacy of early administration of eplerenone in relation to the development of pathological remodeling of the myocardium in patients after myocardial infarction.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005130-22 Sponsor Protocol Number: FFIS/2015/01/ST Start Date*: 2016-08-03
    Sponsor Name:Fundación para la Formación e Investigación Sanitaria (FFIS)
    Full Title: Randomised Controlled Trial with Pravastatin versus Placebo for Prevention of Pre-eclampsia
    Medical condition: Pre-eclampsia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10036585 - Pregnancy, puerperium and perinatal conditions 10036485 Pre-eclampsia PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005181-30 Sponsor Protocol Number: AFT-05/ABCSG-42/BIG_14-03 Start Date*: 2015-07-09
    Sponsor Name:ABCSG GmbH
    Full Title: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor...
    Medical condition: To determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) ES (Ongoing) IE (Ongoing) HU (Ongoing) PT (Ongoing) DE (Ongoing) SE (Ongoing) NL (Ongoing) BE (Ongoing) PL (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2008-008238-35 Sponsor Protocol Number: AMLSG11-08 Start Date*: 2009-06-24
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: Open-Label, Multicenter Phase II Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolidation Therapy as well as in Maintenance Therapy in Patients With Newly Diagnosed Co...
    Medical condition: Newly diagnosed core binding factor acute myeloid leukemia.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001657-28 Sponsor Protocol Number: CTHC002 Start Date*: 2014-01-23
    Sponsor Name:University Medical Center of the Johannes Gutenberg University Mainz
    Full Title: Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban: Prospective Management Trial (HoT-PE)
    Medical condition: Acute low-risk pulmonary embolism (PE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037379 Pulmonary embolism and thrombosis HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) FI (Completed) ES (Completed) NL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003117-18 Sponsor Protocol Number: AMLSG21-13 Start Date*: 2014-07-14
    Sponsor Name:University Hospital Ulm
    Full Title: Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel™) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) AMLSG 21-13
    Medical condition: Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001069-32 Sponsor Protocol Number: D1449L0001 Start Date*: Information not available in EudraCT
    Sponsor Name:Psychosis Early Detection and Intervention Centre, Department for Psychiatry, UKE Hamburg
    Full Title: A prospective 8 weeks acute phase-IV study investigating efficacy, safety and tolerability of Quetiapine fumarate in 60 drug-naïve first-episode psychosis patients aged 18 to 35 years
    Medical condition: A prospective 8 weeks acute phase study investigating efficacy, safety and tolerability of Quetiapine fumarate in 60 drug-naïve first-episode psychosis patients aged 18 to 35 years.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001307-35 Sponsor Protocol Number: FE999906 CS004 Start Date*: 2005-12-22
    Sponsor Name:Ferring Arzneimittel GmbH
    Full Title: A prospective, open label, randomised, parallel group, comparative pilot study to study the efficacy and safety of highly purified Menotrophin versus recombinant FSH (Follitropin alfa) administered...
    Medical condition: sub fertility
    Disease: Version SOC Term Classification Code Term Level
    7.1 10042391 LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003558-26 Sponsor Protocol Number: ABX464-103 Start Date*: 2019-12-10
    Sponsor Name:ABIVAX
    Full Title: A randomized, double blind, placebo controlled, parallel group, multiple dose, induction study to evaluate the safety, tolerability and optimal dose of ABX464 compared with placebo in patients with...
    Medical condition: Moderate to Severe Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10066678 Acute ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SI (Completed) CZ (Completed) DE (Completed) SK (Completed) HU (Completed) PL (Completed) BE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018295-24 Sponsor Protocol Number: AI444-010 Start Date*: 2010-07-12
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection Revised Protocol Number ...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) FR (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-012847-40 Sponsor Protocol Number: Pergoveris_Cetrorelix_1 Start Date*: 2009-11-11
    Sponsor Name:NHS Lothian [...]
    1. NHS Lothian
    2. The University of Edinburgh
    Full Title: A Randomised Study Comparing Two Different Regimens of Ovarian Stimulation Using Pergoveris and Cetrorelix for Controlled Ovarian Superovulation in Assisted Conception Treatment.
    Medical condition: Subfertility
    Disease: Version SOC Term Classification Code Term Level
    12. 10042391 Subfertility LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003679-21 Sponsor Protocol Number: WSG-AM07 Start Date*: 2013-06-27
    Sponsor Name:Westdeutsche Studiengruppe GmbH
    Full Title: A multicenter site, open label, phase II trial to validate predictive markers for the response evaluation of a combined chemo-immunotherapy in patients with HER2-positive early breast cancer
    Medical condition: Early primary breast cancer, hormone receptor positve or negative, HER2 negative, any nodal status
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002189-34 Sponsor Protocol Number: HLX11-BC301 Start Date*: 2022-10-26
    Sponsor Name:Shanghai Henlius Biotech, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Pertuzumab Biosimilar HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy o...
    Medical condition: HER2-Positive and HR-Negative Early-stage or Locally advanced Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:21:01 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA